ISM7713 / Insilico Medicine - LARVOL DELTA

ISM7713, a novel oral pan-KRAS (ON/OFF) inhibitor, shows robust anti-tumor activity in solid tumors with KRAS alterations (AACR 2026) - "Additionally, mini-Ames and off-target safety panel profiling indicated no potential risk. Collectively, these findings highlight the potential of this novel molecule as a potent pan-KRAS (ON/OFF) inhibitor for the treatment of solid tumors with KRAS alterations."

Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • DUSP6 • HRAS • KRAS • NRAS